Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$38.37 USD

38.37
154,984

+0.71 (1.89%)

Updated Nov 6, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View

by Zacks Equity Research

Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.

BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss

by Zacks Equity Research

With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.

Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down

by Zacks Equity Research

Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.

Surging Earnings Estimates Signal Upside for SurModics (SRDX) Stock

by Zacks Equity Research

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.

PRGO or SRDX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PRGO vs. SRDX: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Are Options Traders Betting on a Big Move in Surmodics (SRDX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Surmodics (SRDX) stock based on the movements in the options market lately.

Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller

by Zacks Equity Research

Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller

Why Is SurModics (SRDX) Down 6.2% Since Last Earnings Report?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shrabana Mukherjee headshot

New Analyst Coverage Puts Spotlight on These 5 Stocks

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

by Zacks Equity Research

Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

Shrabana Mukherjee headshot

5 Stocks to Keep an Eye on as Analysts Initiate Coverage

by Shrabana Mukherjee

More analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.

Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Baxter International Now

by Zacks Equity Research

Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.

Here's Why You Should Buy Masimo (MASI) Stock Right Now

by Zacks Equity Research

Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.

BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost

by Zacks Equity Research

Becton, Dickinson (BDX) receives a number of regulatory approvals of late.

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) makes a few lucrative acquisitions in recent times.

Here's Why You Should Hold Becton, Dickinson Stock for Now

by Zacks Equity Research

Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.

DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.

Here's Why You Should Buy Varian Medical (VAR) Stock Now

by Zacks Equity Research

Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.

Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.

Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues

by Zacks Equity Research

Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.

Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.